Physician profile
Mark R Bruss
NPI 1720082423
$1,595.10
in general payments reported to CMS, 2019-2025
34 companies · $18.71 in 2025
The $18.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $223 · 2021: $388 · 2022: $408 · 2023: $278 · 2024: $33.12 · 2025: $18.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.42 | 2021-2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $136.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.56 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.11 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $72.16 | 2020-2022 | |
| Amarin Pharma, INC. | $71.89 | 2019-2022 | |
| Exact Sciences Corporation | $67.58 | 2023-2025 | Cologuard Collection Kit |
| Ucb, INC. | $65.03 | 2021-2023 | Briviact |
| Amgen INC. | $61.83 | 2020-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $60.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.22 | 2019-2022 | |
| Allergan, INC. | $53.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.72 | 2019-2023 | |
| Glaxosmithkline, LLC. | $47.26 | 2022-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $47.03 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.40 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.93 | 2022-2023 | |
| Eisai INC. | $34.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.36 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.77 | 2022-2023 | Austedo |
| Lilly USA, LLC | $25.30 | 2022 | |
| Lundbeck LLC | $20.49 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $20.10 | 2021 | |
| Shield Therapeutics INC | $18.46 | 2023 | Accrufer |
| Vbi Vaccine (Delaware) INC. | $17.01 | 2022 | |
| Sumitomo Pharma America, INC. | $16.36 | 2023 | Gemtesa |
| Genentech USA, INC. | $15.50 | 2021 | |
| Bausch Health US, LLC | $15.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2020 | |
| Corium, LLC | $11.54 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bruss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.